📊 ZNTL Key Takeaways
Is Zentalis Pharmaceuticals, Inc. (ZNTL) a Good Investment?
Zentalis is a pre-revenue, cash-burning pharmaceutical development company with zero revenue and $33M annual operating cash burn against only $31.9M in cash reserves, implying approximately 11-12 months of runway. While the balance sheet is fortress-like with no debt and strong liquidity, the fundamental absence of revenue, persistent losses, and limited financial runway present material solvency risk without successful clinical outcomes or additional financing.
Zentalis Pharmaceuticals, Inc. Key Strengths (ZNTL)
- Zero long-term debt and no financial leverage
- Strong balance sheet with $182.7M stockholders equity and 6.19x current ratio
- Improving loss trajectory with net income losses declining 17.4% year-over-year
- Minimal capital intensity with only $34K capex, preserving cash for operations
ZNTL Stock Risks: Zentalis Pharmaceuticals, Inc. Investment Risks
- Zero revenue with no approved commercial products generating sales
- Operating cash burn of $33M annually against only $31.9M cash, creating critical runway pressure
- Pre-revenue development-stage model dependent on unproven clinical outcomes and regulatory approval
- Limited financial flexibility if development timelines extend or clinical trials fail
- No insider buying activity in past 90 days suggests internal confidence concerns
Key Metrics to Watch
- Cash burn rate trends and cash runway depletion
- Clinical trial progression and regulatory milestone achievements
- Quarterly cash position changes and capital raise activity
- Operating expense management and burn rate improvement
Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.19x current ratio provides a solid financial cushion.
ZNTL Profit Margin, ROE & Profitability Analysis
ZNTL vs Healthcare Sector: How Zentalis Pharmaceuticals, Inc. Compares
How Zentalis Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zentalis Pharmaceuticals, Inc. Stock Overvalued? ZNTL Valuation Analysis 2026
Based on fundamental analysis, Zentalis Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zentalis Pharmaceuticals, Inc. Balance Sheet: ZNTL Debt, Cash & Liquidity
ZNTL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zentalis Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.47 indicates the company is currently unprofitable.
ZNTL Revenue Growth, EPS Growth & YoY Performance
ZNTL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$26.7M | $-0.37 |
| Q2 2025 | N/A | -$26.9M | $-0.37 |
| Q1 2025 | N/A | $10.1M | $0.14 |
| Q3 2024 | N/A | -$40.2M | $-0.56 |
| Q2 2024 | N/A | -$78.2M | $-1.10 |
| Q1 2024 | N/A | $10.1M | $0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zentalis Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ZNTL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zentalis Pharmaceuticals, Inc. (CIK: 0001725160)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZNTL
What is the AI rating for ZNTL?
Zentalis Pharmaceuticals, Inc. (ZNTL) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZNTL's key strengths?
Claude: Zero long-term debt and no financial leverage. Strong balance sheet with $182.7M stockholders equity and 6.19x current ratio.
What are the risks of investing in ZNTL?
Claude: Zero revenue with no approved commercial products generating sales. Operating cash burn of $33M annually against only $31.9M cash, creating critical runway pressure.
What is ZNTL's revenue and growth?
Zentalis Pharmaceuticals, Inc. reported revenue of $0.0.
Does ZNTL pay dividends?
Zentalis Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ZNTL SEC filings?
Official SEC filings for Zentalis Pharmaceuticals, Inc. (CIK: 0001725160) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZNTL's EPS?
Zentalis Pharmaceuticals, Inc. has a diluted EPS of $-0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZNTL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Zentalis Pharmaceuticals, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZNTL stock overvalued or undervalued?
Valuation metrics for ZNTL: ROE of -19.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ZNTL's AI grade for 2026?
Our dual AI analysis gives Zentalis Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZNTL's free cash flow?
Zentalis Pharmaceuticals, Inc.'s operating cash flow is $-33.0M, with capital expenditures of $34.0K.
How does ZNTL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -19.4% (avg: 15%), current ratio 6.19 (avg: 2).